Scientists at the Emory Institute for Drug Discovery will partner with GlaxoSmithKline (GSK) and Alnylam Pharmaceuticals on research aimed at developing new drugs for neglected tropical diseases in least developed countries.
Emory University has signed a Memorandum of Understanding with GSK as the first university to join GSK's new "intellectual property pool," consisting of hundreds of patents and patent applications, scientific reports and analysis. Under the MOU, Emory will have access to GSK scientists who can provide information about the history and current development of selected compounds targeted to the neglected diseases.
Read more at: http://shared.web.emory.edu/emory/news/releases/2010/01/emory-will-partner-with-glaxosmithkline-on-drug-research.html
Subscribe to:
Post Comments (Atom)
Posts
No comments:
Post a Comment